Chardan Capital Issues Pessimistic Forecast for 4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price

4D Molecular Therapeutics (NASDAQ:FDMT) had its target price decreased by Chardan Capital from $39.00 to $30.00 in a research note issued to investors on Tuesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

FDMT has been the topic of several other reports. Morgan Stanley reduced their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research note on Monday, January 13th. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Leerink Partners decreased their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Bank of America decreased their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and an average target price of $32.13.

4D Molecular Therapeutics Trading Up 3.7 %

NASDAQ:FDMT opened at $4.72 on Tuesday. The firm has a market cap of $218.21 million, a price-to-earnings ratio of -1.66 and a beta of 2.81. 4D Molecular Therapeutics has a 12-month low of $4.41 and a 12-month high of $36.25. The company’s 50-day moving average is $5.65 and its two-hundred day moving average is $9.49.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC boosted its holdings in 4D Molecular Therapeutics by 141.0% in the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after purchasing an additional 67,202 shares during the period. Novo Holdings A S lifted its stake in shares of 4D Molecular Therapeutics by 7.1% in the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after purchasing an additional 100,000 shares during the period. nVerses Capital LLC bought a new stake in 4D Molecular Therapeutics in the third quarter valued at approximately $40,000. Braidwell LP grew its position in shares of 4D Molecular Therapeutics by 231.7% in the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after purchasing an additional 855,990 shares during the period. Finally, State Street Corp boosted its stake in 4D Molecular Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after purchasing an additional 37,232 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.